

Jeannine S Mccune

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2775685/jeannine-s-mccune-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129
papers

3,934
citations

36
h-index

56
g-index

136
ext. papers

4,551
ext. citations

4.3
avg, IF

5.2
L-index

#	Paper	IF	Citations
129	Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: A NaPDI Center recommended approach. <i>Clinical and Translational Science</i> , 2021 ,	4.9	1
128	Concepts and Applications of Information Theory to Immuno-Oncology. <i>Trends in Cancer</i> , 2021 , 7, 335-346.	16.5	2
127	Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. <i>Blood</i> , 2021 ,	2.2	6
126	Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients. <i>Bone Marrow Transplantation</i> , 2021 , 56, 726-729	4.4	
125	Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning. <i>Journal of Proteome Research</i> , 2021 , 20, 684-694	5.6	1
124	Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach. <i>Pharmacological Reviews</i> , 2021 , 73, 847-859	22.5	2
123	Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29203	3	0
122	Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 657-663	3.2	0
121	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020 , 11, 962-972	10.3	5
120	A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies. <i>Drug Metabolism and Disposition</i> , 2020 , 48, 1104-1112	4	1
119	Environmental Exposures during Puberty: Window of Breast Cancer Risk and Epigenetic Damage. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	12
118	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e235-e236	4.7	
117	Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 48-56	7.1	1
116	Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach. <i>Natural Product Reports</i> , 2019 , 36, 1196-1221	15.1	49
115	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. <i>Blood</i> , 2019 , 134, 211-215	2.2	10
114	A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. <i>Pharmacology & Therapeutics</i> , 2019 , 201, 25-38	13.9	36
113	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1424-1431	4.7	9

112	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 1070-1082	21.7	101
111	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1890-1897	4.7	15
110	Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 552-560	4	17
109	Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1802-1807	4.7	7
108	Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. <i>International Journal of Hyperthermia</i> , 2018 , 34, 284-291	3.7	21
107	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018 , 13, e0198389	3.7	51
106	Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 1041-1045	4	15
105	Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 1046-1052	4	14
104	Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC) – An ACCRU Network study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 611-611	2.2	27
103	Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018 , 132, 620-620	2.2	
102	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2770-2777	2.2	74
101	Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. <i>Journal of Oncology Pharmacy Practice</i> , 2017 , 23, 344-349	1.7	9
100	Comparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (<i>Camellia sinensis</i>) as a Case Study. <i>Journal of Natural Products</i> , 2017 , 80, 1457-1466	4.9	38
99	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017 , 3, 1675-1682	13.4	78
98	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. <i>Journal of Comparative Effectiveness Research</i> , 2017 , 6, 461-470	2.1	7
97	Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. <i>Lancet Haematology, the</i> , 2016 , 3, e516-e525	14.6	8
96	Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics. <i>Metabolomics</i> , 2016 , 12, 1	4.7	12
95	Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 525-50	6.2	20

94	Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 551-93	6.2	16
93	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016 , 128, 216-216	2.2	16
92	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10528-10528	2.2	3
91	Pharmacogenetics of treatment response in patients with high-risk neuroblastoma: A Children's Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10560-10560	2.2	
90	Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoietic Cell Transplant Recipients. <i>Journal of Proteome Research</i> , 2016 , 15, 2802-11	5.6	17
89	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016 , 127, 1502-8	2.2	119
88	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1582-1587	4.7	12
87	The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. <i>Oncologist</i> , 2016 , 21, 320-6	5.7	51
86	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1915-1925	4.7	82
85	Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. <i>Cancer Research</i> , 2015 , 75, 3738-46	10.1	54
84	Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 67-75	3.5	9
83	Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. <i>Bone Marrow Transplantation</i> , 2015 , 50, 165-72	4.4	11
82	Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 85-96	3.5	10
81	Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians. <i>Journal of Biomedical Informatics</i> , 2015 , 55, 249-59	10.2	21
80	Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality. <i>Blood</i> , 2015 , 126, 532-532	2.2	4
79	Costs and resource utilization associated with skeletal related events in Medicare patients with prostate cancer metastatic to bones.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6612-6612	2.2	2
78	Impact of skeletal-related events on survival in patients with prostate cancer metastatic to bones.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 223-223	2.2	
77	Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM model to optimize dosing. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 839-47	2.8	13

76	Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: a mixed methods approach. <i>International Journal of Medical Informatics</i> , 2014 , 83, 473-83	5.3	54
75	Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1121-9	4.7	16
74	Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1544-52	4.7	4
73	Predictive performance of a physiologically based pharmacokinetic model of busulfan in children. <i>Pediatric Hematology and Oncology</i> , 2014 , 31, 731-42	1.7	19
72	Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. <i>Clinical Cancer Research</i> , 2014 , 20, 754-63	12.9	94
71	A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 607-18	3.5	5
70	Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1033-9	4.7	54
69	Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 991-1000	3.5	8
68	Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1159-66	4.7	26
67	Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 393-402	2.9	33
66	Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 264-75	2.9	31
65	Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013 , 60, 621-6	3	25
64	High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013 , 51, 711-7	2	12
63	Patterns of blood product use among patients with myelodysplastic syndrome. <i>Vox Sanguinis</i> , 2012 , 102, 331-7	3.1	10
62	A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 263-72	3.5	15
61	Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 586-94	2.9	22
60	Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 265-72	4.7	43
59	Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy. <i>Pharmacotherapy</i> , 2012 , 32, 7-19	5.8	11

58	Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2012 , 47, 581-8	4.4	34
57	A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 1654-64 ⁹	2.9	13
56	Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 54-63	4	37
55	Health care use and primary prophylaxis with colony-stimulating factors. <i>Value in Health</i> , 2011 , 14, 247-53 ³	3.3	6
54	Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 1429-38	2.9	32
53	A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions. <i>Journal of Alternative and Complementary Medicine</i> , 2011 , 17, 1043-9	2.4	6
52	Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2345-54	15.9	86
51	Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 1292-300	2.9	26
50	Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes. <i>Scientia Pharmaceutica</i> , 2010 , 78, 473-81	4.3	36
49	Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. <i>American Journal of Managed Care</i> , 2010 , 16, 678-86	2.1	33
48	Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 88-102	2.9	32
47	A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. <i>Clinical Cancer Research</i> , 2009 , 15, 5280-7	12.9	19
46	A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 391-401	3.5	18
45	Intracellular disposition of fludarabine triphosphate in human natural killer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 959-64	3.5	5
44	Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 615-22	6.1	57
43	Busulfan in hematopoietic stem cell transplant setting. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 957-69	5.5	76
42	Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig. <i>Transplantation</i> , 2009 , 88, 317-22	1.8	22
41	Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by Targeted Intravenous Busulfan) in Allogeneic Hematopoietic Cell Transplantation: Preliminary Results of a Prospective Clinical Trial.. <i>Blood</i> , 2009 , 114, 1175-1175	2.2	2

40	Optimal prevention of seizures induced by high-dose busulfan. <i>Pharmacotherapy</i> , 2008 , 28, 1502-10	5.8	64
39	Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. <i>Pharmacogenomics Journal</i> , 2008 , 8, 248-55	3.5	12
38	Imatinib inhibition of fludarabine uptake in T-lymphocytes. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 735-9	3.5	11
37	Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 760-4	4.7	25
36	Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 853-62	4.7	75
35	Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. <i>Clinical Cancer Research</i> , 2006 , 12, 4888-98	12.9	31
34	Current status of cetuximab for the treatment of patients with solid tumors. <i>Annals of Pharmacotherapy</i> , 2006 , 40, 241-50	2.9	30
33	Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 573-84	4.7	75
32	Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1352-4	4.7	18
31	Cyclophosphamide disposition in an anephric child. <i>Pediatric Blood and Cancer</i> , 2006 , 46, 99-104	3	12
30	Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 835, 105-13	3.2	29
29	A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 465-71	4.7	71
28	A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. <i>Cancer Investigation</i> , 2005 , 23, 511-9	2.1	2
27	A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 495-505	4.7	108
26	Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005 , 28, 270-6	2.7	28
25	A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005 , 820, 243-50	3.2	14
24	Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 298-308	6.1	26
23	The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. <i>Cancer</i> , 2005 , 104, 2054-62	6.4	25

22	The absolute bioavailability of oral vinorelbine in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56, 578-84	3.5	20
21	Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?. <i>Genetics in Medicine</i> , 2005 , 7, 380-9	8.1	57
20	Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 1074-81	4	51
19	Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors. <i>Journal of Oncology Pharmacy Practice</i> , 2005 , 11, 37-43	1.7	8
18	Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. <i>Blood</i> , 2005 , 106, 4381-8	2.2	67
17	Potential of chemotherapy-herb interactions in adult cancer patients. <i>Supportive Care in Cancer</i> , 2004 , 12, 454-62	3.9	102
16	Influence of age upon Ifosfamide-induced nephrotoxicity. <i>Pediatric Blood and Cancer</i> , 2004 , 42, 427-32	3	19
15	Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. <i>Anti-Cancer Drugs</i> , 2004 , 15, 453-9	2.4	37
14	Topotecan disposition in an anephric child. <i>Journal of Pediatric Hematology/Oncology</i> , 2004 , 26, 596-600	1.2	11
13	Myalgias and arthralgias associated with paclitaxel. <i>Oncology</i> , 2003 , 17, 271-7; discussion 281-2, 286-8	1.8	20
12	Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002 , 30, 167-73	4.4	95
11	The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 814-22	4	78
10	Pharmacological considerations of primary alkylators. <i>Cancer Treatment and Research</i> , 2002 , 112, 323-45	3.5	4
9	Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47, 373-9	3.5	30
8	Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. <i>Journal of Clinical Pharmacology</i> , 2001 , 41, 723-31	2.9	45
7	In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 356-66	6.1	110
6	Granulocyte colony-stimulating factor use in cancer patients. <i>Annals of Pharmacotherapy</i> , 2000 , 34, 851-2.	2.9	15
5	Plasma concentration monitoring of busulfan: does it improve clinical outcome?. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 155-65	6.2	118

4	Perception of chemotherapy side effects cancer versus noncancer patients. <i>Cancer Practice</i> , 1999 , 7, 59-65		123
3	Cancer pain survey: patient-centered issues in control. <i>Journal of Pain and Symptom Management</i> , 1998 , 15, 275-84	4.8	85
2	Appropriateness of maximum-dose guidelines for vincristine. <i>American Journal of Health-System Pharmacy</i> , 1997 , 54, 1755-8	2.2	27
1	The essential research curriculum for doctor of pharmacy degree programs â2021. <i>JACCP Journal of the American College of Clinical Pharmacy</i> ,	1.4	1